Skip to main content
. 2018 Oct 1;3(1):195–202. doi: 10.1089/can.2018.0029

FIG. 1.

FIG. 1.

Barriers to discussing medical cannabis with qualified patients: average rating score and percent of responses to each response scale (1–5). FDA, Food and Drug Administration; MN, Minnesota.